globenewswire

FORM 8.5 (EPT/RI)

AMSTERDAM, June 12, 2026 (GLOBE NEWSWIRE) -- For more than a century, HEINZ and Heineken^® have played a role in bringing people together… around tables, in front of screens, at events, and beyond. Now the two iconic brands have officially come together to celebrate a connection of their own — giving everyone the match we’ve all been waiting for.

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido^®  (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial⁷. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines⁷.

“Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité–Universitätsmedizin Berlin, Germany. “The RemIND results across the three most common CIndU subtypes highlight the potential of Rhapsido as an important new treatment option for patients with significant unmet need.”

The three most prevalent CIndU subtypes are symptomatic dermographism (SD), cold urticaria, and cholinergic urticaria, with SD being the most common⁸. Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Rhapsido for the treatment of SD subtype and will continue additional filings to health authorities globally throughout 2026. Rhapsido is approved for use in the U.S., European Union, China and several other countries for the treatment of chronic spontaneous urticaria (CSU), in adult patients with inadequate response to H1-antihistamines.

“Rhapsido significantly improves symptom control for patients living with the three most common subtypes of chronic inducible urticaria, and it has the potential to become the first approved targeted therapy. This is a major step forward for CIndU patients who have limited options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “The CIndU data presented today are consistent with Rhapsido’s proven efficacy and favorable safety profile in chronic spontaneous urticaria and demonstrate Novartis’ commitment to developing truly meaningful innovation for patients with complex immune-mediated diseases.”

Primary endpoint results at Week 12 in the RemIND trial¹

Transaction in Own Shares

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- PHX Energy Services Corp. ("PHX Energy" or the "Corporation") is pleased to announce that its Board of Directors has declared a quarterly cash dividend of $0.20 per common share designated as an “eligible dividend” within the meaning of subsection 89(1) of the Income Tax Act (Canada), payable on July 15, 2026, to shareholders of record at the close of business on June 30, 2026.

Worn by 12 million American women, Shapermint joined Extra TV's coverage of fashion's two biggest nights to make the case that every confident look, on the red carpet or off, starts with the right foundation

DUBAİ, Birleşik Arap Emirlikleri, June 12, 2026 (GLOBE NEWSWIRE) -- Futbol dünyasında bazı isimler, saha içindeki başarılarını emeklilik sonrasında kurumsal birer vizyona dönüştürmeyi başarır. İngiltere Premier Lig'in son çeyrek asrına damga vuran John Terry, bu dönüşümün spor tarihindeki en profesyonel örneklerinden biri olarak kabul ediliyor. Chelsea formasıyla kazandığı sayısız kupa ve taraftarlarca kalbine kazınan "Kaptan, Lider, Efsane" kimliği, Terry için bugün küresel iş dünyasında kapıları açan en büyük anahtar haline gelmiş durumda.